Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alkermes, Inc.
Pharmaceutical company reports loss of $0.82 per share
June 22nd, 2005
Alkermes, Inc., (ALKS) reported its financial results for the fiscal year ended March 31, 2005. The net loss on a GAAP basis for the fiscal year was $73.9 million or $0.82 per share as compared to a net loss of $102.4 million or $1.25 per share in the prior year. "The progress Alkermes made during fiscal 2005 has been dramatic. Risperdal Consta revenues grew strongly, we submitted our New Drug Application for Vivitrex to the Food and Drug Administration, and we demonstrated significant clinical progress with our diabetes pipeline," stated Richard Pops, chief executive officer of Alkermes. "Looking forward to fiscal 2006, we...
Source: Physician Law Weekly (2005-06-22)
|
